Stockreport

JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma

NovoCure Limited - Ordinary Shares  (NVCR) 
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
PDF The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients wit [Read more]